Management’s tone is strongly optimistic (“unmatched” excitement; “incredibly pleased”), anchored on EFZO-FIT progressing through four DSMB reviews with no safety flags and on the FDA accepting a cleaner steroid-reduction SAP definition. However, Q&A pressure quickly revealed areas where precision and commercialization certainty are limited. The FDA change was not market-research driven; it was an “inside baseball” pre-hoc biostatistics alignment, shifting from an average-week-12-to-48 approach to absolute change from week 0 to week 48. While powering remains “over 90%,” management acknowledged that detailed endpoint magnitude impacts (e.g., how the Phase 1/2 1.6 mg/day figure would translate under the new definition) were not re-calculated—only qualitatively inferred to be larger. Expanded access interest is robust, but management refused to give a rollover percentage due to center/country regulatory constraints (Japan explicitly cannot participate). Net: confident clinical path and clearer analysis, but investors still lack quantitative certainty around endpoint translation and real-world EAP uptake.

Sentiment: MIXED